• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Discovery of dihydropyrrolidones as novel inhibitors against influenza A virus

tetano

Editor, Senior Moderator
Eur J Med Chem. 2020 May 4;199:112334. doi: 10.1016/j.ejmech.2020.112334. [Epub ahead of print]
Discovery of dihydropyrrolidones as novel inhibitors against influenza A virus.


Liu T[SUP]1[/SUP], Dai C[SUP]1[/SUP], Sang H[SUP]1[/SUP], Chen F[SUP]1[/SUP], Huang Y[SUP]1[/SUP], Liao H[SUP]1[/SUP], Liu S[SUP]1[/SUP], Zhu Q[SUP]2[/SUP], Yang J[SUP]3[/SUP].

Author information




Abstract

More effective prophylactic and therapeutic strategies to combat influenza viruses are urgently required worldwide because the conventional anti-influenza drugs are facing drug resistance. Here, dihydropyrrolidones (DHPs), the products of an efficient multi-components reaction, were found to possess good activities against influenza A virus (IAV). Primary structure-activity relationship indicated that the activities of DHPs were greatly influenced by substituents and four of them had IC[SUB]50[/SUB] values lower than 10 μM (DHPs 5-2, 8, 14 and 19: IC[SUB]50[/SUB] = 3.11-9.23 μM). The activities against multiple IAV strains and mechanism of DHPs were further investigated by using 5-2 (IC[SUB]50[/SUB] = 3.11 μM). It was found that 5-2 possessed antiviral effects against all the investigated subtypes of IAVs with the IC[SUB]50[/SUB] values from 3.11 to 7.13 μM. Moreover, 5-2 showed very low cytotoxicity with CC[SUB]50[/SUB] > 400 μM. Results of mechanism study indicated that 5-2 could efficiently inhibit replication of IAV, up-regulate the expression of key antiviral cytokines IFN-β and antiviral protein MxA, and suppress the production of the NDAPH oxidase NOX1 in MDCK cells. These results indicated that 5-2 could be used as a potential inhibitor against wide subtypes of IAVs.
Copyright ? 2020 Elsevier Masson SAS. All rights reserved.



KEYWORDS:

Design and synthesis; Dihydropyrrolidones; Immunity regulation; Influenza a virus; Structure-activity relationship


PMID:32408213DOI:10.1016/j.ejmech.2020.112334
 
Back
Top Bottom